Early research (Phase 1)Study completedNCT07226778
What this trial is testing
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Who this might be right for
OverweightObesity
Amgen 348